MA46266A - Formes cristallines - Google Patents

Formes cristallines

Info

Publication number
MA46266A
MA46266A MA046266A MA46266A MA46266A MA 46266 A MA46266 A MA 46266A MA 046266 A MA046266 A MA 046266A MA 46266 A MA46266 A MA 46266A MA 46266 A MA46266 A MA 46266A
Authority
MA
Morocco
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
MA046266A
Other languages
English (en)
Other versions
MA46266B1 (fr
Inventor
Daniel Leuenberger
Stefan Reber
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA46266A publication Critical patent/MA46266A/fr
Publication of MA46266B1 publication Critical patent/MA46266B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA46266A 2016-09-22 2017-09-21 Formes cristallines MA46266B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (fr) 2016-09-22 2017-09-21 Formes cristallines

Publications (2)

Publication Number Publication Date
MA46266A true MA46266A (fr) 2019-07-31
MA46266B1 MA46266B1 (fr) 2022-02-28

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46266A MA46266B1 (fr) 2016-09-22 2017-09-21 Formes cristallines

Country Status (27)

Country Link
US (4) US10730896B2 (fr)
EP (2) EP3515924B1 (fr)
JP (1) JP7097369B2 (fr)
KR (1) KR102552795B1 (fr)
CN (1) CN109715639B (fr)
AU (1) AU2017331930B2 (fr)
CA (1) CA3037794A1 (fr)
CL (1) CL2019000728A1 (fr)
CY (1) CY1125052T1 (fr)
DK (1) DK3515924T3 (fr)
EA (1) EA201990723A1 (fr)
ES (1) ES2908572T3 (fr)
HR (1) HRP20220234T1 (fr)
HU (1) HUE057772T2 (fr)
IL (1) IL265445B2 (fr)
LT (1) LT3515924T (fr)
MA (1) MA46266B1 (fr)
MX (1) MX381590B (fr)
MY (1) MY193080A (fr)
PH (1) PH12019500567B1 (fr)
PL (1) PL3515924T3 (fr)
PT (1) PT3515924T (fr)
RS (1) RS62946B1 (fr)
SI (1) SI3515924T1 (fr)
TW (1) TWI752086B (fr)
UA (1) UA124073C2 (fr)
WO (1) WO2018055016A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物
CA3223733A1 (fr) 2021-07-13 2023-01-19 Nicole Blumer Procede de synthese d'ester de butyle d'acide 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (fr) 1989-07-05 1991-01-06 Yoshihide Fuse Derive de cinnamamide
CA2375920A1 (fr) 1999-06-14 2000-12-21 Eli Lilly And Company Composes
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
WO2004092189A1 (fr) 2003-04-09 2004-10-28 Wyeth Derives d'acide 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonique et leur utilisation comme antagonistes du recepteur n-methyl-d-aspartate (nmda)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (fr) 2007-04-23 2008-10-30 Sanofi-Aventis Derives de quinoleine-carboxamide comme antagonistes de p2y12
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238127B1 (fr) 2007-12-26 2012-08-15 Sanofi Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物

Also Published As

Publication number Publication date
CL2019000728A1 (es) 2019-07-05
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
DK3515924T3 (da) 2022-03-21
NZ750772A (en) 2023-10-27
IL265445B2 (en) 2024-05-01
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
TW201813965A (zh) 2018-04-16
US12227532B2 (en) 2025-02-18
AU2017331930A1 (en) 2019-03-07
HUE057772T2 (hu) 2022-06-28
EP3515924A1 (fr) 2019-07-31
MX381590B (es) 2025-03-12
EP3515924B1 (fr) 2021-12-15
CY1125052T1 (el) 2024-02-16
IL265445B1 (en) 2024-01-01
JP2019529553A (ja) 2019-10-17
US20210009614A1 (en) 2021-01-14
TWI752086B (zh) 2022-01-11
SI3515924T1 (sl) 2022-04-29
WO2018055016A1 (fr) 2018-03-29
EP3981774A1 (fr) 2022-04-13
US11365209B2 (en) 2022-06-21
US20250163086A1 (en) 2025-05-22
KR20190052704A (ko) 2019-05-16
PH12019500567B1 (en) 2024-01-31
US20220275011A1 (en) 2022-09-01
JP7097369B2 (ja) 2022-07-07
EA201990723A1 (ru) 2019-10-31
ES2908572T3 (es) 2022-05-03
MX2019003093A (es) 2019-07-18
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
LT3515924T (lt) 2022-03-10
KR102552795B1 (ko) 2023-07-06
BR112019004845A2 (pt) 2019-06-04
HRP20220234T1 (hr) 2022-05-13
AU2017331930B2 (en) 2021-07-15
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
CN109715639B (zh) 2022-04-19
CA3037794A1 (fr) 2018-03-29
MA46266B1 (fr) 2022-02-28
MY193080A (en) 2022-09-26
CN109715639A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
PL3978483T3 (pl) Krystaliczny solwat toluenowy (S)-afoksolaneru
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
PT3157915T (pt) Compostos de dihidroisoquinolinona substituídos
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
PT3298027T (pt) Compostos depsipéptidos antelmínticos
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3455077C0 (fr) Impression
EP3435660A4 (fr) Visiocasque
SMT202200173T1 (it) Composti
EP3227309C0 (fr) Difucosyllactose cristallin
LT3597189T (lt) Kristaliniai junginia
LT3362444T (lt) Junginiai
EP3309163A4 (fr) Dérivé de dihydropyrrolopyrazole substitué
EP3390422A4 (fr) Formes cristallines de lnt
DK3819287T3 (da) Amorft tapentadolphosphat
MA46567A (fr) Formes cristallines de l'éravacycline
HUE043622T2 (hu) Tároló
EP3454846A4 (fr) Cristaux
LT3331885T (lt) Junginiai
DK3672941T3 (da) Pyridylpyridonforbindelser
LT3515924T (lt) Kristalinės formos
EP3426675A4 (fr) Formes salines cristallines
EP3454107A4 (fr) Visiocasque
DK3672962T3 (da) Morpholinylpyridonforbindelser
ES1159683Y (es) Protesis neovaginal